Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera

[Business Wire] – Incyte Corporation today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of ach more

View todays social media effects on INCY

View the latest stocks trending across Twitter. Click to view dashboard

See who Incyte is hiring next, click here to view